SCHEMBL310905

SCHEMBL310905

CCOc1cc(-c2ccncc2)ccc1N

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.77
HSD17B10 Q99714 4/20 0.77
MEN1 O00255 3/20 0.77
KMT2A Q03164 3/20 0.77
HPGD P15428 3/20 0.77
MAPT P10636 2/20 0.77
KDM4E B2RXH2 2/20 0.77
POLB P06746 1/20 0.77
MAPK1 P28482 1/20 0.77
L3MBTL1 Q9Y468 1/20 0.77
AAK1 Q2M2I8 1/20 0.53
S1PR1 P21453 9/20 0.52
S1PR3 Q99500 3/20 0.49
CYP3A4 P08684 3/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP17A1 P05093 1/20 0.46
CYP19A1 P11511 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136308 0.88 ALDH1A1 (1.00) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL2779956 0.84 ALDH1A1 (0.85) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL3781455 0.83 ALDH1A1 (0.82) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL28136363 0.81 ALDH1A1 (0.74) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL26381942 0.81 ALDH1A1 (0.85) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL3783982 0.77 ALDH1A1 (0.77) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL13253645 0.76 S1PR1 (0.49) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL6753624 0.75 ALDH1A1 (0.73) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL30705088 0.74 ALDH1A1 (0.66) ALDH1A1HSD17B10MEN1KMT2AHPGD
SCHEMBL22430892 0.74 ALDH1A1 (0.61) ALDH1A1HSD17B10MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ALDH1A1 3410/4885HSD17B10 4656/4885MEN1 2992/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 ALDH1A1 3410/4885HSD17B10 4656/4885MEN1 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.